Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive <i>EGFR</i>-mutant Non-small Cell Lung Cancer.

Yu, Helena A; Paz-Ares, Luis G; Yang, James Chih-Hsin; Lee, Ki Hyeong; Garrido, Pilar; Park, Keunchil; Kim, Joo-Hang; Lee, Dae Ho; Mao, Huzhang; Wijayawardana, Sameera R; Gao, Ling; Hozak, Rebecca R; Chao, Bo H; Planchard, David

Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer.

Yu, Helena A; Paz-Ares, Luis G; Yang, James Chih-Hsin; Lee, Ki Hyeong; Garrido, Pilar; Park, Keunchil; Kim, Joo-Hang; Lee, Dae Ho; Mao, Huzhang; Wijayawardana, Sameera R; Gao, Ling; Hozak, Rebecca R; Chao, Bo H; Planchard, David.

Affiliation

Yu HA; Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York. yuh@mskcc.org.
Paz-Ares LG; Medical Oncology Department, University Hospital 12 de Octubre, Madrid, Spain.
Yang JC; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
Lee KH; Division of Hematology and Oncology, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea.
Garrido P; Medical Oncology Department, Hospital Ramón y Cajal, Madrid, Spain.
Park K; Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Kim JH; Division of Medical Oncology, Department of Internal Medicine, CHA Bundang Medical Center, Gyeonggi, Republic of Korea.
Lee DH; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine Seoul, Seoul, Republic of Korea.
Mao H; Eli Lilly and Company, Indianapolis, Indiana.
Wijayawardana SR; Eli Lilly and Company, Indianapolis, Indiana.
Gao L; Eli Lilly and Company, Indianapolis, Indiana.
Hozak RR; Eli Lilly and Company, Indianapolis, Indiana.
Chao BH; Eli Lilly and Company, New York, New York.
Planchard D; Department of Medical Oncology, Thoracic Unit, Gustave Roussy, Villejuif, France.

Clin Cancer Res ; 27(4): 992-1002, 2021 02 15.

Article in En | MEDLINE | ID: mdl-33046516

Subject(s)

Acrylamides/administration & dosage; Aniline Compounds/administration & dosage; Antibodies, Monoclonal, Humanized/administration & dosage; Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Carcinoma, Non-Small-Cell Lung/drug therapy; Lung Neoplasms/drug therapy; Acrylamides/adverse effects; Aged; Aged, 80 and over; Aniline Compounds/adverse effects; Antibodies, Monoclonal, Humanized/adverse effects; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Carcinoma, Non-Small-Cell Lung/diagnosis; Carcinoma, Non-Small-Cell Lung/genetics; Carcinoma, Non-Small-Cell Lung/mortality; Disease-Free Survival; ErbB Receptors/antagonists & inhibitors; ErbB Receptors/genetics; Female; Humans; Lung Neoplasms/diagnosis; Lung Neoplasms/genetics; Lung Neoplasms/mortality; Male; Middle Aged; Mutation; Neoplasm Staging; Progression-Free Survival; Response Evaluation Criteria in Solid Tumors; Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors; Ramucirumab

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Acrylamides / Antineoplastic Combined Chemotherapy Protocols / Carcinoma, Non-Small-Cell Lung / Antibodies, Monoclonal, Humanized / Aniline Compounds / Lung Neoplasms Type of study: Clinical_trials / Diagnostic_studies Limits: Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Year: 2021 Document type: Article

Fulltext

XML

PubMed Links

Search on Google